The p53 gene suppresses tumor cell growth by inducing cell cycle arrest or apoptosis. Loss of its apoptosis activity has been implicated not only in tumor development but also in chemoresistance. We previously reported that targeting p53 for degradation by the human HPV E6 gene in the ovarian cancer cell line PA1 leads to an increase in the chemoresistant phenotype. Here we investigate the relationship between loss of p53-dependent caspase activation and chemosensitivity. In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation. Importantly, we showed that loss of caspase activation in PA1-E6 cells correlates with increased cell survival. Moreover, PA1 cells overexpressing a dominant negative caspase 9 were found to have decreased caspasedependent apoptosis, as compared with vector control cells. Furthermore, these dominant negative caspase 9 expressing cells were resistant to chemotherapeutic agent-induced killing. Our results suggest that caspase 9 may be an important target for anticancer drug development. Thus, identifying novel compounds that can activate caspase 9 may be a strategy for overcoming a defect in the p53 apoptosis pathway.
Introduction
Programmed cell death or apoptosis is a genetically controlled mechanism essential for the maintenance of tissue homeostasis, proper tissue development and the elimination of unwanted cells. At the biochemical level, the process of apoptosis is involved in an ordered activation of a set of cysteine proteases called caspases (Alnemri et al., 1996) . Caspases exist as inactive proenzymes that must be activated by proteolytic cleavage after speci®c aspartate residues (Gu et al., 1995) . Based on their roles in apoptosis, caspases are divided into initiator caspases, including caspases 8, 9 and 10, and executioner caspases, including caspases 3, 6, and 7 (Cryns and Yuan, 1998; Green, 1998) . At the molecular level, apoptosis is initiated from signals through death receptors or the mitochondria (Cryns and Yuan, 1998; Green, 1998) .
It has been shown that the activation of the mitochondrial pathway involves the release of cytochrome c from the mitochondria to the cytosol in response to a variety of apoptotic stimuli, such as DNA damage, anticancer drug treatment and growth factor withdrawal. Once cytochrome c releases into the cytosol, it can associate with Apaf1 and procaspase 9 in the presence of dATP, leading to activation of caspase 9 (Li et al., 1997) . Subsequently, activated caspase 9 cleaves downstream caspases, such as caspases 3, 6 and 7, leading to cell death (Srinivasula et al., 1998) . This intrinsic pathway can be activated by many apoptotic stimuli including the p53 tumor suppressor gene.
The p53 tumor suppressor gene is the most commonly mutated gene in human cancer. p53 acts as a tumor suppressor through its ability to induce cell cycle arrest or apoptosis in response to a variety of stresses, such as DNA damage, oncogene activation, and hypoxia. Whereas p53-mediated cell cycle arrest may be transient, p53-induced apoptosis is irreversible and potent in preventing tumor growth. Decreases in apoptosis correlate with the occurrence of p53 mutations in transgenic mice (Symonds et al., 1994) . Loss of p53 markedly attenuates radiation and druginduced apoptosis in a variety of murine tissues (Lotem and Sachs, 1993; Lowe et al., 1993b Lowe et al., , 1994 .
Although the role of p53 in apoptosis is undisputed, the mechanism by which p53 induces apoptosis is not fully understood (Lowe et al., 1993a,b) . Studies have suggested that p53-mediated apoptosis involves both transcription-dependent and ± independent mechanisms (Attardi et al., 1996; Caelle et al., 1994; Haupt et al., 1995; Sabbatini et al., 1995) . Much eort has gone into characterizing the transcriptional activation of its targets and a number of genes including Bax (Miyashita et al., 1994b, Miyashita and Reed, 1995) , Fas/APO1 (Owen-Schaub et al., 1995) , KILLER/DR5 (Wu et al., 1997 (Wu et al., , 1999 , Pigs (Polyak et al., 1997) , PERP (Attardi et al., 2000) , noxa (Oda et al., 2000a) , p53AIP1 (Oda et al., 2000b) , PIDD and PUMA (Nakano and Vousden, 2001; Yu et al., 2001) have been implicated in p53-mediated apoptosis. On the other hand, little is known about p53-mediated apoptosis through a transcription-independent mechanism, but it is believed that p53 may suppress some genes, such as Bcl2 (Miyashita et al., 1994a) , whose expression may be involved in regulating p53-dependent apoptosis. Several lines of evidence suggest that caspases are activated during p53-mediated apoptosis, but the mechanism by which this activation occurs is unclear. It has been shown that the combination of IL3 withdrawal and exposure to ionizing radiation induces rapid p53-dependent apoptosis accompanied by caspase-mediated cleavage of the tumor suppressor protein Rb (Gottlieb and Oren, 1998) . Consistent with this ®nding, p53 was found to induce caspase activation in both cell-based systems (Schuler et al., 2000) and cell-free systems through direct protein-protein interaction (Ding et al., 1998 (Ding et al., , 2000 . Interestingly, through the use of knockout technology, caspase 9 and its cofactor Apaf1 have been found to be essential downstream components of p53 in Myc-induced apoptosis (Soengas et al., 1999) . A recent study reported that inactivation of Apaf1 is associated with chemoresistance in metastatic melanoma (Soengas et al., 2001) . Taken together, these data suggest that caspases play important roles in p53-dependent apoptosis and chemosensitivity.
In this study, we investigated the relationship between loss of p53-dependent caspase activation and chemosensitivity using a human ovarian cancer PA1 cell system (Wu and El-Deiry, 1996a ). Here we report that caspases are activated in PA1-neo cells but not in PA1-E6 cells following adriamycin or etoposide treatment and such activation correlates with chemosensitivity in PA1 cells. More importantly, we show that overexpression of a dominant negative caspase 9 (DN-casp 9) protects PA1 cells from apoptosis induced by adriamycin or etoposide. Furthermore, we show that in PA1 cells expressing DN-casp 9, there is a decrease in caspase activation, which correlates with increased cell survival, similar to the eects observed with loss of functional p53 in PA1-E6 cells. Therefore, our result suggests that caspase 9 plays an important role in chemosensitivity in PA1 ovarian cancer cells.
Results

Loss of functional p53 leads to inability of caspases to be activated in PA1 cells
We have previously shown that targeting p53 for degradation by the HPV E6 gene confers PA1 cell resistance to taxol-induced killing (Wu and El-Deiry, 1996a) . To further investigate the mechanism of p53-dependent chemosensitivity, we examined the activation of caspases in PA1-neo and PA1-E6 cells following treatment with adriamycin. We chose adriamycin at 0.3 mg/ml, because this concentration was found to cause cytotoxicity of PA1 cells in preliminary experiments. Following adriamycin treatment both detached and attached PA1-neo and PA1-E6 cells were harvested at 8, 12 and 24 h and total proteins were extracted for assessing activation of caspases. Figure 1a shows that in PA1-neo cells, caspases 9, 8, 7 and 3 were cleaved by a treatment with adriamycin at 24 h, as opposed to PA1-E6 cells in which no such changes were observed. Subsequently, cleavage of PARP, a hallmark of apoptosis and substrate of caspases 3 and 7, was detectable at 12 h and signi®cant at 24 h ( Figure 1a lane 4 versus lane 8) in PA1-neo but not evident in E6 cells.
It has been shown that chemotherapeutic agents can induce apoptosis through multiple pathways, mainly by targeting the mitochondrial pathway to cause cytochrome c release and activation of caspases. Therefore, we reasoned that inactivation of caspases in chemotherapeutic agent-treated PA1-E6 cells may be due to an inability of cytochrome c to be released from the mitochondria to the cytosol. To test this possibility, we treated the cells with adriamycin for 12 and 24 h, respectively, and then examined the release of cytochrome c. Figure 1b shows that there is more cytochrome c released in the cytosol in PA1-neo cells than in PA1-E6 cells (lane 3 versus lane 6), suggesting release of cytochrome c in PA1 cells is partially dependent on p53. In order to validate these observations with another drug, we chose etoposide, a topoisomerase II inhibitor and a potent p53 inducer. In etoposide-treated PA1-neo cells, activation of caspases 9, 7 and 3, and cleavage of PARP were observed at 12 h and 24 h, respectively ( Figure 1c ). In contrast, such changes were not detected in etoposide-treated PA1-E6 cells ( Figure  1c ). In addition, we also found that the release of cytochrome c is greater in PA1-neo cells than in PA1-E6 cells (data not shown). Taken together, these results indicate that loss of p53 in PA1-E6 cells impairs cytochrome c release and decreases caspase activation and apoptosis induction.
Although the E6 gene has been widely used to target p53 protein for degradation (Kessis et al., 1993; Fan et al., 1995) , E6 is also reported to target other cellular proteins (Tong and Howley, 1997) , raising a concern that the dierence in caspase activation between PA1-neo and PA1-E6 cells might not be related to the loss of p53. To address this, we used HCT116 p53 +/+ cells and their matched HCT116 p53 7/7 cells in which p53 has been knockout by homologous recombination (Bunz et al., 1999) . We treated HCT116 p53 +/+ cells and HCT116 p53
7/7 cells with 5-FU, whose anticancer activity in colon cancer cells is p53 dependent (Bunz et al., 1999) , and the total cellular protein was extracted after 24 and 48 h for assessment of caspase 3 activation and PARP cleavage. As shown in Figure 2 , cleavage of caspase 3 and PARP was detected in 5-FU treated HCT116 p53 +/+ p53 and chemosensitivity GS Wu and Z Ding cells but not evident in p53 7/7 cells, suggesting that loss of p53 impairs 5-FU-induced caspase activation and subsequent apoptosis. We also found that activation of caspases 9 and 7 was detected only in HCT116 p53
7/7 cells (data not shown), consistent with a previous report that HCT116 p53
7/7 cells were much more resistant than HCT116 p53 7/7 cells to 5-FUinduced killing (data not shown) (Bunz et al., 1999) . Thus, our results suggest that loss of p53-dependent caspase activation renders some cell types resistant to certain chemotherapeutic agents.
Loss of p53-dependent caspase activation correlates with chemoresistance in PA1 cells
We have previously shown that PA1-E6 cells are more resistant to taxol-induced killing in a short-term survival assay than their counterpart PA1-neo cells (Wu and El-Deiry, 1996a) . Because PA1-E6 cells were unable to trigger a caspase cascade upon adriamycin or etoposide treatment as shown above, it is possible that loss of p53-mediated caspase activation is associated with an increase in the survival of PA1-E6 cells. To test this, we treated PA1-neo and PA1-E6 cells with adriamycin or etoposide for 1 week and assessed their clonogenic survival abilities. As shown in Figure 3a , following a treatment with adriamycin (4 ng/ml), about 55% of PA1-E6 cells survived as compared with zero survived PA1-neo cells. Similarly, with etoposide treatment at 0.2 mM, about 65% of PA1-E6 cells survived, as opposed to zero survival of PA1-neo cells (Figure 3b ). These results suggest that loss of functional p53 may impair p53-dependent activation of caspases, and in turn increase chemoresistance in human ovarian cancer cells.
Overexpression of dominant negative caspase 9 (DN-casp 9) blocks caspase activation induced by chemotherapeutic agents
It is believed that chemotherapeutic agent-induced apoptosis involves multiple pathways, with preferential activation of the mitochondrial pathway. Caspase 9 is Figure 1 The activation of the caspase cascade in ovarian cancer cells. PA1-neo and PA1-E6 cells were treated with adriamycin at 0.3 mg/ml (a and b) or etoposide at 0.3 mM (c) for 0, 8, 12 and 24 h. The cells were collected and total cell lysates (a and c) or mitochondrial fraction (b) were prepared for analysing the activation of caspases including caspases 9, 8, 7 and 3, as well as cleavage of PARP (a and c) or release of cytochrome c (b) by Western blotting as described in Materials and methods. N.S., nonspeci®c Figure 2 Loss of p53 confers HCT116 cell resistance to 5-FUinduced apoptosis. HCT116 p53 +/+ and p53 7/7 cells were left untreated or treated with 5-FU at 375 mM for 1 or 2 days. The cells were collected and cell lysates were prepared for analysing caspase 3 and PARP cleavage by Western blotting as described in Materials and methods the apical caspase in the mitochondrial pathway. It has been shown that Apaf1 and caspase 9 are essential downstream components of p53 in Myc-induced apoptosis (Soengas et al., 1999) . It is reasonable therefore to assume that loss of caspase 9 activation might mimic, at least in part, loss of p53, leading to chemoresistance, as observed with PA1-E6 cells. To test this possibility, PA1 cells were transfected with an empty vector, pcDNA3, or a T7-tagged full length caspase 9 with the active site mutation (C287A) (Li et al., 1997) , pcDNA3-DN-caspase 9 (DN-casp 9), and selected with G418 for clones that stably expressed the T7-DN-casp 9 protein. Western blot analysis using T7 antibody was employed to screen for clones in which transfected DN-casp 9 was expressed. As expected, a 46 kD band, corresponding to T7 DN-casp 9, was detected in pcDNA3-DN-casp 9 transfected clones (Figure 4, lanes 8 and 10) , but not in vector-transfected cells (Figure 4, lanes 1 and 2) , as well as clones with low levels of DN-casp 9 (Figure 4, lanes 3, 4 and 7) . To investigate the eect of DN-casp 9 expression on caspase activation, both PA1-vector and PA1-DN-casp 9 (clone #8) cells were treated with adriamycin (0.3 mg/ ml) at dierent time points and activation of caspases was then examined. As shown in Figure 5a , activation of caspases 9, 7 and 3, as well as cleavage of PARP, was detected in vector-transfected cells at 12 and 24 h following adriamycin treatment and caspase 8 cleavage was detectable at 24 h. In contrast, all changes except caspase 8 cleavage were inhibited in the cells expressing DN-casp 9 (Figure 5a ), suggesting that the blockade of caspase 9 activation by DN-casp 9 is sucient to block downstream caspase activation and subsequent apoptosis. To further con®rm this observation with another anticancer agent, we treated both DN-casp 9 and vector transfected cells with etoposide and examined the activation of caspases. As shown in Figure 5b , activation of caspase 3 was detected in vectortransfected cells whereas a corresponding change was not detected in cells expressing DN-casp 9. Consistent with activation of caspase 3, PARP was cleaved in vector cells but not in DN-casp 9 cells (Figure 5b , lanes 3 and 4 versus lanes 7 and 8). We also found that activation of caspase 9 was inhibited in DN-casp 9 cells but not in vector cells (data not shown). In addition, we evaluated the activation of caspases and cleavage of PARP in another clone (#10) and similar results were obtained (data not shown). Thus, these results indicate that overexpression of DN-casp 9 suciently inhibits chemotherapeutic agent-induced caspase activation and thereby inhibits apoptosis in PA1 cells.
Overexpression of DN-casp 9 renders PA1 cells resistant to chemotherapy
Since overexpression of DN-casp 9 in PA1 cells decreased activation of caspases and since decreases (lanes 1 and 2) or DN-casp 9 expressing vector (lanes 3 ± 11), followed by selection with G418 (500 mg/ml) for 2 weeks. Individual clones were isolated and their cell lysates were analysed on a 15% SDS ± PAGE, transferred to nitrocellulose, and probed with a monoclonal antibody to T7 (Novagen, Inc, Madison). Clones 8 and 10 expressed high levels of DN-casp 9 protein p53 and chemosensitivity GS Wu and Z Ding in caspase activation correlated with an increase in chemoresistance in PA1-E6 cells, it is conceivable that such a decrease in caspase activation by overexpression of DN-casp 9 may aect chemosensitivity. To test this possibility, we examined the chemosensitivity of PA1-vector and DN-casp 9 cells (clone #8) to adriamycin and etoposide. As shown in Figure 6a , about 40% of DN-casp 9 cells survived, compared with about 8% survival of vector-transfected cells following treatment with adriamycin at 4 ng/ml. Consistently, 45% of DN-casp 9 cells survived, compared with none of the vector-transfected cells following treatment with etoposide at 0.1 mM ( Figure  6b ). We con®rmed that DN-casp 9 PA1 cells expressed wild-type p53 as evidenced by the induction of p53 and p21 following treatment with adriamycin or etoposide (Figure 6c and data not shown). Similar results were obtained with another clone (#10) (data not shown). Thus, our results suggest that the blockade of caspase 9 activation can mimic, at least in part, loss of functional p53, thereby impairing caspase-dependent apoptosis, leading to increased chemoresistance.
Discussion
In this study, we demonstrated that loss of functional p53 in PA1-E6 cells abolishes activation of the caspase cascade in response to chemotherapeutic agent treatment. Importantly, it was shown that PA1-E6 cells are more resistant to adriamycin or etoposide-induced killing, as compared with the PA1-neo cells. Furthermore, we showed that in PA1 cells, the blockade of caspase 9 activation by DN-casp 9 results in decreased caspase-dependent apoptosis and chemosensitivity, which is similar to loss of functional p53 in PA1-E6 cells. Thus, these ®ndings suggest that in some cell types, such as PA1 cells, p53-dependent caspase activation in response to chemotherapeutic agent treatment is critical for chemosensitivity. Though p53 has been implicated as a determinant of chemosensitivity in tumor cells, the results are inconsistent. In some cases, targeting p53 protein for degradation by human papillomavirus (HPV) E6 protein has led to altered chemosensitivity (Slichenmyer et al., 1993) and loss of p53 also correlates with malignant tumor progression and drug resistance in vivo in many tumor types (Velculescu and El-Deiry, 1996) . However, another study has shown that loss of p53 confers increased sensitivity to chemotherapeutic agents (Fan et al., 1995) . By knockout of p53, the human colon cancer cell line HCT116 was rendered more sensitive to adriamycin and etoposide but much more resistant to 5-FU (Bunz et al., 1999) . Therefore, the role of p53 in chemosensitivity is believed to be cell-type and drug-type dependent. We have previously shown that p53 status correlates with chemosensitivity in ovarian cancer cell lines (Wu and El-Deiry, 1996b) and in PA1-E6 cells loss of p53 protein results in a chemoresistant phenotype (Wu and El-Deiry, 1996a) . In this study, we have shown that loss of p53 correlates with a decrease in p53-dependent caspase activation and increased chemoresistance. Therefore, there is a correlation between p53-dependent caspase activation and chemosensitivity in some cell types, as observed in PA1 cells in this study and in HCT116 cells in response to 5-FU treatment (Bunz et al., 1999) . Thus, this ®nding may provide an explanation for the role of p53 in chemosensitivity in the cells whose p53 status correlates with chemosensitivity.
It is well established that p53 is activated by a variety of stress stimuli including DNA damage and chemotherapeutic agents, many of which are believed to be DNA damaging agents. It has been shown that anti-cancer agents kill tumor cells through apoptosis and that the activation of p53 by anticancer agent treatment triggers apoptosis of cancer cells (Blagosklonny, 2000) . Therefore, it is conceivable that impairing the p53-dependent apoptosis pathway may result in decreased chemosensitivity. In support of this, we have shown that cleavage of caspases 9, 8, 7 and 3, PARP, and release of cytochrome c, are detected in PA1-neo cells following adriamycin or etoposide treatment and these cells undergo apoptosis (Figure 1) . However, PA1-E6 cells failed to activate Actin Actin Figure 5 Overexpression of DN-casp 9 blocks activation of the caspase cascade. PA1-vector or PA1-DN-casp 9 were left untreated or treated with adriamycin (a) or etoposide (b) for 8, 12, and 24 h. Total cellular protein was prepared for analysis of the activation of caspases including caspases 9, 8, 7 and 3, and cleavage of PARP by Western blotting as described in Materials and methods such a caspase cascade and were resistant to killing by these two agents (Figure 1 ), suggesting that p53-dependent caspase activation is a critical event for chemosensitivity in PA1 cells. Although we did not investigate how p53 triggers a caspase cascade, our results clearly showed that activation of caspases is required for p53-mediated apoptosis and chemosensitivity because loss of p53 in PA1-E6 cells failed to do so. Consistent with these ®ndings, HCT 116 p53 7/7 cells failed to undergo apoptosis and were resistant to 5-FU-induced killing, as opposed to HCT116 p53 +/+ cells (Bunz et al., 1999) . HCT116 p53 7/7 cells were unable to cleave caspase 3 and PARP, while such changes were fully activated in HCT116 p53 +/+ cells (Figure 3 and data not shown). Thus, it is tempting to speculate that measuring p53-dependent caspase activation may be useful to predict chemosensitivity in some cell types.
How does loss of p53 result in the impairment of caspase-dependent apoptosis and chemoresistance in PA1 cells? It has been shown that p53 can transcriptionally regulate a number of genes whose expression has been implicated in apoptosis. For example, two death receptors Fas/APO1 and KILLER/DR5 are regulated by p53 and are involved in apoptosis by activating the death receptor pathway (Owen-Schaub et al., 1995; Wu et al., 1997 Wu et al., , 1999 . On the other hand, the activation of other p53 targets including Bax (Miyashita et al., 1994b; Miyashita and Reed, 1995) , PERP (Attardi et al., 2000) , noxa (Oda et al., 2000a) , p53AIP1 (Oda et al., 2000b) , PIDD and PUMA (Nakano and Vousden, 2001; Yu et al., 2001) can induce apoptosis via the mitochondrial pathway. Since both pathways culminate in the activation of a caspase cascade, it is not surprising that p53-mediated apoptosis involves the caspase cascade. We have shown that activation of caspases including caspases 9, 8, 7 and 3 are observed in adriamycin or etoposide treated PA1-neo cells, as compared with PA1-E6 cells in which such changes were not evident (Figure 1) , implying a role of p53 in controlling the activation of the caspase cascade in this model system. These ®ndings are consistent with the recent reports that p53 plays an important role in apoptosis by controlling activation of caspases 8 and 9 (Ding et al., 1998 (Ding et al., , 2000 Schuler et al., 2000) . Importantly, loss of caspase 9 and Apaf1 has been reported to confer mouse ®broblast resistance to apoptosis and promote tumor development in a mouse model (Soengas et al., 1999) . Consistently, a recent study showed that Apaf1 is a transcriptional target for p53 (Moroni et al., 2001) . Thus, our ®ndings, along with these reports, suggest that activation of caspases is required for p53-mediated apoptosis in some cell types.
It is believed that chemotherapeutic agent-induced apoptosis is predominantly accomplished by activation of the mitochondrial pathway. We have shown that the blockade of caspase 9 activation by DN-casp 9 decreases chemotherapeutic agent-induced caspase activation and subsequent apoptosis (Figures 5 and 6) . Therefore, our results are in agreement with other reports that Apaf1 and caspase 9 play a critical role for DNA damage induced apoptosis (Fearnhead et al., 1998; Perkins et al., 2000) . In this study, we have clearly shown that the blockade of caspase 9 activation can substitute for the loss of p53-mediated apoptosis and chemosensitivity, which is in agreement with the role of caspase 9 and Apaf1 in p53-mediated apoptosis and tumor suppression (Moroni et al., 2001; Soengas et al., 1999 Soengas et al., , 2001 . Therefore, our work makes a connection between p53 status, caspase 9 activation, apoptosis induction and chemosensitivity in ovarian cancer PA1 cells. Given the fact that p53 is mutated in more than 50% of human cancer and some tumors may be de®cient in the p53 pathway either by inactivating the upstream signal pathway, such as the ARF ± MDM2 pathway (Sherr, 1998) , or the downstream apoptosis pathway (i.e. Apaf1 methylation) (Soengas et al., 2001) , our work may have an important application for screening compounds that can activate caspase 9 and induce apoptosis to overcome p53 mutations to serve as anticancer therapy.
In summary, we have found that loss of p53 impairs caspase-dependent apoptosis of the mitochondrial pathway and renders PA1-E6 cells insensitive to anticancer drug-induced killing. Overexpression of DN-casp 9 confers resistance to chemotherapeutic agent-mediated apoptosis and chemosensitivity of PA1 cells. Our results indicate that caspase 9 is an important target for anticancer drug development. Future experiments will focus on the mechanisms by which p53 regulates caspase 9 activation and modulation of caspase 9 activation sensitizes tumor cells to chemotherapeutic agents.
Materials and methods
Cell lines and culture conditions
The human ovarian cancer cell lines PA1, PA1-neo and PA1-E6 were maintained in basal modi®ed Eagle's medium as described previously (Wu and El-Deiry, 1996b) . The human colon cancer cell lines HCT116 p53 +/+ and HCT116 p53 7/7 , a generous gift from Dr Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA), were maintained in McCoy's media as described (Bunz et al., 1999) . These cells were supplemented with 10% fetal bovine serum and antibiotics at 378C in a humidi®ed atmosphere consisting of 5% CO 2 and 95% air. The chemotherapeutic agents adriamycin, etoposide and 5-FU were obtained from the Oncology Outpatient Pharmacy at the Karmanos Cancer Institute. Cells were grown in the presence of various concentrations of chemotherapeutic agents for the dierent time points as indicated in the individual ®gure legends.
Generation of PA1 cells expressing dominant negative caspase 9
To generate cell lines in which the dominant negative caspase 9 gene (DN-casp 9) was overexpressed, PA1 cells were transfected with either pcDNA3, an empty vector, or pcDNA3-DN-casp 9, an expression vector containing a T7-tagged full length caspase 9 with the active site mutation at C287A (a gift from Dr Emad Alnemri, Thomas Jeerson University, Philadelphia, PA, USA) as described (Li et al., 1997) . Following 2 weeks of selection in the presence of 500 mg/ml of G418 (GIBCO/BRL, Rockville, MD, USA), individual clones were isolated as described previously (Wu and El-Deiry, 1996b ). Using anti-T 7 antibody (Novagen, Inc, Madison), two clones that expressed T7 protein determined by Western blot analysis were used for this study.
Clonogenic survival assay
Cells were plated at a density of 5000/well (in triplicate) and treated with dierent concentrations of adriamycin or etoposide as described (Wu and El-Deiry, 1996b; Wu et al., 1998) . After a 7-day treatment, cells were stained with crystal violet. The resulting cells were destained with 10% acetic acid followed by measuring at 600 nm. Clonogenic survival was calculated as described (Sun et al., 2001) .
Measurement of cytochrome c release
Cells were plated onto 75-cm diameter¯asks one day before treatment. At various time points following treatment with adriamycin or etoposide, both¯oating and attached cells were harvested and cytosolic cytochrome c was extracted as described (Sun et al., 2001) . Brie¯y, harvested cells were resuspended in ice-cold lysis buer (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 20 ml protease inhibitors (Sigma, St. Louis, MO, USA), 4 mM dithiothreitol, and 1 mM phenylmethylsulfonyl¯uoride) containing 250 mM sucrose, and incubated for 1 h at 48C. The lysates were passed through a 26 gauge syringe 15 times and then centrifuged at 10000 r.p.m. for 20 min at 48C. The resulting supernatant was analysed by immunoblot analysis using anti-cytochrome c antibody (ZYMED Laboratories Inc, South San Francisco, CA, USA) as described below.
Western blot analysis
Whole cell lysates from both attached and¯oating cells were prepared as described (Sun et al., 2001 ) and protein concentration was determined using the Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Cell lysates (50 mg) were electrophoresed through 7.5 ± 12% denaturing polyacrylamide slab gels and transferred to a nitrocellulose membrane (Schleicher & Schuell, Inc., Keene, NH, USA) by electroblotting. The blots were probed or reprobed with antibodies, and bound antibody was detected using Enhanced Chemiluminescence Reagent (Amersham Pharmacia, Piscataway, NJ, USA) according to the manufacturer's protocol. Mouse monoclonal anti-caspase-7 (clone B94-1) was purchased from PharMingen (San Diego, CA, USA). Goat polyclonal anticaspase-8 (C-20) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit polyclonal anticaspase-9 and rabbit polyclonal anti-PARP were purchased from New England Biolabs, Inc. (Beverly, MA, USA). Mouse anti-caspase-3 (Ab1) and anti-actin were purchased from Calbiochem (Boston, MA, USA).
